A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri)
at steady state.
The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin
saturation) of Tysabri at steady state.